SCHEMBL1091065

SCHEMBL1091065

COC(=O)c1ccc2c(c1)SCCC2=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.60
HTT P42858 2/20 0.60
ALDH1A1 P00352 6/20 0.51
HSD17B10 Q99714 3/20 0.50
ALOX15 P16050 2/20 0.50
CASP1 P29466 2/20 0.50
CASP7 P55210 2/20 0.50
LMNA P02545 2/20 0.47
HPGD P15428 3/20 0.46
MAPT P10636 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
FGB P02675 1/20 0.46
HSP90AA1 P07900 1/20 0.46
HSP90AB1 P08238 1/20 0.46
MAPK1 P28482 1/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
POLB P06746 3/20 0.46
NPSR1 Q6W5P4 2/20 0.45
ATM Q13315 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31247524 1.00 KDM4E (0.60) KDM4EHTTALDH1A1HSD17B10ALOX15
SCHEMBL5956836 0.92 KDM4E (0.50) KDM4EHTTALDH1A1HSD17B10ALOX15
SCHEMBL2263868 0.88 ALDH1A1 (0.53) KDM4EHTTALDH1A1HSD17B10ALOX15
SCHEMBL5956466 0.78 ALDH1A1 (0.54) KDM4EHTTALDH1A1HSD17B10ALOX15
SCHEMBL21383082 0.78 ALDH1A1 (0.61) KDM4EHTTALDH1A1HSD17B10ALOX15
SCHEMBL3142775 0.77 ALDH1A1 (0.57) KDM4EHTTALDH1A1HSD17B10ALOX15
SCHEMBL67590 0.75 KDM4E (1.00) KDM4EHTTALDH1A1LMNACA12
SCHEMBL31532073 0.75 SRD5A1 (0.51) KDM4EALDH1A1HSD17B10CASP1CASP7
SCHEMBL883773 0.75 SRD5A1 (0.51) KDM4EALDH1A1HSD17B10CASP1CASP7
SCHEMBL27355436 0.75 ALDH1A1 (0.51) KDM4EHTTALDH1A1HSD17B10ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739684-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 EP disclosed
US-12595230-B2 Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof SANOFI (FR) 2026-04-07 US disclosed
US-20250248970-A1 NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2025-08-07 US disclosed
EP-4508031-A1 NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF Sanofi (FR) 2025-02-19 EP disclosed
WO-2025008060-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 WO disclosed
EP-4228758-B1 SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI SA (FR) 2024-07-24 EP disclosed
US-20230382854-A1 Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds and Their Derivatives, Processes for Their Preparation and Therapeutic Uses Thereof SANOFI (FR) 2023-11-30 US disclosed
US-20230382854-A1 Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds and Their Derivatives, Processes for Their Preparation and Therapeutic Uses Thereof SANOFI (FR) 2023-11-30 US disclosed
US-20230382854-A1 Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds and Their Derivatives, Processes for Their Preparation and Therapeutic Uses Thereof SANOFI (FR) 2023-11-30 US disclosed
WO-2023198879-A1 NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF SANOFI (FR) 2023-10-19 WO disclosed
EP-2840076-A1 BICYCLIC COMPOUND TOA Eiyo Ltd. (JP) 2015-02-25 EP disclosed
US-8153671-B2 Heterotetracyclic compounds as TPO mimetics IRM LLC (BM) 2012-04-10 US disclosed
EP-1910338-B1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2010-08-25 EP disclosed
US-20090075996-A1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2009-03-19 US disclosed
EP-1910338-A2 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM, LLC (BM) 2008-04-16 EP disclosed
WO-2007009120-A2 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS IRM LLC (BM) 2007-01-18 WO disclosed
EP-1270570-B1 AMIDE COMPOUNDS AND USE THEREOF MITSUBISHI PHARMA CORP (JP) 2006-05-31 EP disclosed
US-6933305-B2 Amide compounds and use thereof MITSUBISHI PHARMA CORPORATION (JP) 2005-08-23 US disclosed
US-20030158413-A1 Amide compounds and use thereof MITSUBISHI PHARMA CORPORATION (JP) 2003-08-21 US disclosed
EP-1270570-A1 AMIDE COMPOUNDS AND USE THEREOF Mitsubishi Pharma Corporation (JP) 2003-01-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075996-A1 HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS MPL, TPO, THPO KDM4E 4685/4885HTT 397/4885ALDH1A1 1941/4885
US-20230382854-A1 Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds and Their Derivatives, Processes for Their Preparation and Therapeutic Uses Thereof ESRRA, ESR2, FSHR KDM4E 2095/4885HTT 3614/4885ALDH1A1 1348/4885
US-20030158413-A1 Amide compounds and use thereof ROCK2, ROCK1, RHOT2 KDM4E 1686/4885HTT 3077/4885ALDH1A1 2624/4885
US-12595230-B2 Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof FSHR, CYP19A1, GPER1 KDM4E 1708/4885HTT 3697/4885ALDH1A1 936/4885
US-20250248970-A1 NOVEL SUBSTITUTED FLUORINATED N-PROPYL-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF FSHR, ESRRA, GPER1 KDM4E 1180/4885HTT 2861/4885ALDH1A1 2275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.